



US009439906B2

(12) **United States Patent**
Vermeulen et al.

(10) **Patent No.:** US 9,439,906 B2
(45) **Date of Patent:** Sep. 13, 2016

(54) **DOSING REGIMEN ASSOCIATED WITH
LONG ACTING INJECTABLE
PALIPERIDONE ESTERS**

(75) Inventors: **An Vermeulen**, Beerse (BE); **Alfons Wouters**, Beerse (BE)

(73) Assignee: **Janssen Pharmaceutica NV** (BE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 770 days.

(21) Appl. No.: **12/337,144**

(22) Filed: **Dec. 17, 2008**

(65) **Prior Publication Data**

US 2009/0163519 A1 Jun. 25, 2009

Related U.S. Application Data

(60) Provisional application No. 61/014,918, filed on Dec. 19, 2007, provisional application No. 61/120,276, filed on Dec. 5, 2008.

(51) **Int. Cl.**

C07D 471/04 (2006.01)

A61K 31/445 (2006.01)

A61K 31/41 (2006.01)

A61K 31/42 (2006.01)

A61K 31/519 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/519** (2013.01)

(58) **Field of Classification Search**

CPC . A61K 31/519; A61K 9/0019; A61K 9/0024

USPC 514/257, 323, 360, 379

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,804,663	A	2/1989	Kennis et al.
5,158,952	A	10/1992	Janssen et al.
5,254,556	A	10/1993	Janssen et al.
5,453,425	A	9/1995	Francois et al.
5,612,346	A	3/1997	Mesens et al.
6,077,843	A	6/2000	François et al.
6,555,544	B2	4/2003	François et al.
6,577,545	B2	6/2003	Kim et al.
2002/0082245	A1	6/2002	Yelle
2003/0157180	A1	8/2003	Francois et al.
2007/0197591	A1	8/2007	Boom et al.
2009/0163519	A1	6/2009	Vermeulen et al.
2011/0105536	A1	5/2011	Lewyn-Briscoe et al.
2012/0263795	A1	10/2012	Francois et al.

FOREIGN PATENT DOCUMENTS

WO	2004/010981	2/2004
WO	WO 2006/114384	11/2006
WO	2008/021342	2/2008
WO	2009/025859	2/2009
WO	2009/047499	4/2009
WO	2009/080651	7/2009
WO	2011/053829	5/2011

OTHER PUBLICATIONS

Alphs L, Bossie C, Sliwa JK, Ma YW, Haskins T Tolerability of Paliperidone Palmitate Initiation Doses in Subjects With Recently

Diagnosed Schizophrenia. Poster No. NR6-21 at the 163rd Annual Meeting of the American Psychiatric Association (APA), New Orleans, Louisiana, USA, May 22-26, 2010.

Alphs L, Haskins, Bossie C, Sliwa JK, Gopal S, Hough D, Davis J Long-term Metabolic Outcomes With Paliperidone Palmitate, A Once-Monthly Long-Acting Injectable Antipsychotic Agent, in the Treatment of Subjects With Schizophrenia. Poster No. 204 at the 48th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, Florida, USA, December 6-10, 2009.

Cleton A, Rossenu S, Crauwels H, Berwaerts J, Hough D, Gopal S, Eerdeken M, Vandebosch A, Rosso Fernandez C Assessment of the Dose Proportionality of Paliperidone Palmitate 25, 50, 100 and 150 mg eq., A New Long-Acting Injectable Antipsychotic, Following Administration in the Deltoid or Gluteal Muscles. Poster at the 2008 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), Orlando, Florida, USA, Apr. 2-5, 2008. Coppola D, Liu Y, Gopal S, Remmerie B, Samtani M, Pandina G, Hough D, Nuamah I, Sulaiman A Long-Term Safety, Tolerability and Pharmacokinetics of Paliperidone Palmitate 234 mg (150 mg eq.), The Highest Marketed Dose: A One-Year Open-Label Study in Patients With Schizophrenia. Poster No. PI-49 at the 2010 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), Atlanta, Georgia, USA, Mar. 17-20, 2010. Gopal S, Berwaerts J, Nuamah I, Akhras K, Coppola D, Daly E, Hough DW, Palumbo JM Efficacy and Safety of Long-Acting Injectable Paliperidone Palmitate Relative to Long-Acting Haloperidol, Bromperidol and Fluphenazine Decanoate for Long-Term Treatment in Patients With Schizophrenia Using Number Needed to Treat and Number Needed to Harm. Poster at the 65th Annual Convention and Scientific Program of the Society of Biological Psychiatry (SOBP), New Orleans, Louisiana, USA, May 20-22, 2010.

Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L, Practical Guidance for Dosing and Switching Paliperidone Palmitate Treatment in Patients with Schizophrenia, Current Medical Research and Opinion 26 (2), p. 377-387, 2010.

Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdeken MH, Brown DW, Efficacy and Safety of Paliperidone Palmitate in Adult Patients with Acutely Symptomatic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study, International Clinical Psychopharmacology, pp. 247-256 (2010).

Gopal S, Lindenmayer JP, Hough D, Melkote R, Lim P, Eerdeken M, Safety and Tolerability of the Investigational Antipsychotic Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Patients with Schizophrenia, 63rd Annual Convention and Scientific Program of the Society of Biological Psychiatry (SOBP), Washington, DC, USA, May 1-3, 2008, Biological Psychiatry 63 (7, Suppl. 7), p. 285S, 2008.

Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdeken M Long-Term Efficacy, Safety and Tolerability of Paliperidone Palmitate in Patients with Schizophrenia. Poster No. 20 at the 12th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP), Jacksonville, Florida, Apr. 19-22, 2009.

(Continued)

Primary Examiner — Sreeni Padmanabhan

Assistant Examiner — Jody Karol

(57) **ABSTRACT**

The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.

21 Claims, 3 Drawing Sheets